Core Insights - The article discusses the significance of organoids as advanced 3D models derived from stem cells, which closely mimic human tissue complexity and functionality, offering advantages over traditional 2D cell lines and animal models in drug discovery and disease modeling [1][2]. Group 1: Organoid Applications - Organoids can be utilized for disease modeling, drug screening, and safety assessments, providing a more physiologically relevant environment compared to 2D cell lines [2][12]. - The potential for personalized medicine is highlighted, as organoids can be generated from patient-derived cells, allowing for individualized drug testing [2][12]. Group 2: Comparison with Other Models - Organoids exhibit high physiological relevance, effectively mimicking human tissue complexity, while 2D cell lines have limited structural mimicry and animal models present interspecies differences [3]. - In terms of throughput, organoids offer medium to high capabilities, constrained by growth complexity, whereas 2D cell lines are high throughput but lack physiological relevance [3]. Group 3: Challenges and Future Directions - Despite advancements, challenges remain in the scalability and reproducibility of organoid cultures, particularly for high-throughput screening [12]. - Innovations are needed in vascularization, immune system integration, and multi-organ modeling to enhance the predictive capabilities of organoids for human therapeutic responses [12].

（文章来源：每日经济新闻） 每经AI快讯，众生药业（002317.SZ）12月16日在投资者互动平台表示，公司昂拉地韦颗粒III期临床试 验正在积极推进中，目前已完成全部参与者入组工作。公司争取早日完成相关研究，申报药物上市，为 广大患者提供更多治疗选择。公司将严格按照相关规则及要求履行决策程序和信息披露义务。 ...

美国密歇根州立大学研究团队利用捐赠的人类干细胞，成功开发出全球首个"人源化"心脏类器官，能在 暴露于炎症环境时表现出心房颤动特征。这一突破为研究心律失常提供了前所未有的活体人体组织模 型，有望打破该领域30多年来无新药问世的僵局。这项发表于《细胞·干细胞》的研究，标志着人类在 对抗心律失常的道路上迈出了关键一步。 心房颤动影响全球约6000万人，但由于缺乏准确的人类心脏模型，药物研发长期停滞。近30多年来，没 有新药物被开发用于治疗心房颤动。现有疗法往往针对症状而非潜在机制，因此人们对这种疾病仍然治 疗不力。 2020年起，密歇根州立大学发育与干细胞生物学部艾托·阿吉雷团队利用捐赠的人类干细胞，培育出直 径约数毫米的三维心脏类器官。这些类器官不仅拥有类似真实心脏的腔室结构和血管网络，还能自主节 律性跳动。而且这些类器官的节律性搏动非常强劲，无需显微镜即可观察到。 类器官大小与扁豆相仿，精确度极高，使团队能够以前所未有的方式研究心脏发育、疾病和药物反应。 此次研究的关键进展在于，团队首次在类器官中引入了免疫细胞。博士后研究员科林·奥罗克发现，当 类器官暴露于炎症环境时，会出现类似房颤的心律失常；而使用抗炎药物后 ...

格隆汇12月12日丨康弘药业(002773.SZ)公布，子公司成都弘基生物科技有限公司（简称"弘基生物"）收 到国家药品监督管理局签发的《药物临床试验批准通知书》，药品名称：KH658眼用注射液。本品适用 于治疗糖尿病黄斑水肿（DME）、糖尿病视网膜病变（DR）。 ...

Core Viewpoint - Dyne Therapeutics is experiencing significant investor interest following a positive analyst upgrade and promising clinical trial results for its investigational drug, leading to a notable increase in stock price [1][2][4]. Group 1: Analyst Upgrade - Jay Olson of Oppenheimer upgraded Dyne's stock recommendation from hold to outperform, nearly quadrupling the price target from $11 to $40 [2]. - The upgrade coincided with the release of positive results from a clinical trial, suggesting a strong potential for the company's drug [4]. Group 2: Clinical Trial Results - Dyne's investigational drug, zeleciment rostudirsen, successfully met both primary and secondary endpoints in a phase 1/2 clinical trial for Duchenne muscular dystrophy (DMD) [4]. - The drug was found to effectively increase the production of dystrophin, a protein crucial for muscle protection [5]. Group 3: Market Performance - Dyne's stock rose by 6.78% to a current price of $19.69, with a market capitalization of $3 billion [6]. - The stock has shown volatility, with a recent secondary stock offering causing initial investor concerns, but the positive trial results have renewed optimism [9]. Group 4: Future Plans - The company aims to submit zeleciment rostudirsen for accelerated FDA approval in the second quarter of 2026, indicating a proactive approach to advancing its drug pipeline [8].

Core Insights - A new study reveals that vertebrates can regenerate a complex lymphoid organ, the thymus, from scratch without any tissue remnants, expanding the understanding of organ regeneration capabilities [1][2] - The research highlights the thymus's critical role in the immune system and its limited repair ability in most animals, which deteriorates with age, leading to decreased immune function [1] Group 1: Research Findings - The study, published in the journal Science Immunology, demonstrates the thymus regeneration ability of the Mexican axolotl, known for its limb regeneration [1] - The research team conducted a series of experiments, including precise thymectomy and high-resolution imaging, confirming the complete dynamic process of thymus regeneration [1] - After 35 days, the axolotl developed a new thymus that matched the original in morphology, cell types, and function [1] Group 2: Mechanisms and Implications - The research team utilized single-cell RNA sequencing to map the stages of thymus regeneration, identifying two signaling pathways as key to initiating this process: bone morphogenetic protein and a lesser-known "regeneration initiator" called midfactor [2] - The findings suggest potential therapeutic avenues for activating similar signaling pathways in humans, which could benefit children who have undergone thymus surgery, patients with specific immune deficiencies, and elderly individuals with declining immune function [2] - The study points to a new drug development pathway, with ongoing exploration of critical issues such as identifying "seed cells" that initiate regeneration, understanding how the size and location of the regenerated organ are precisely regulated, and verifying the effectiveness of related signaling pathways in mammals [2]

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 CLOUDBREAK PHARMA INC. CBT-004是一種潛在的同類首創眼科藥物，採用多激酶抑制劑，靶向血管內皮生長因子受體及血小板 衍生生長因子受體，適用於治療血管化瞼裂斑。本集團於2023年12月開始CBT-004的第2期臨床試驗， 並於2025年5月完成。結果表明，CBT-004 在受試者中是安全且耐受性良好的，並在療效方面達到 了主要終點以及若干次要終點。本集團已於2025年7月完成臨床試驗報告並計劃與美國食品及藥物管 理局舉行第2期臨床試驗後會議。 撥 康 視 雲 製 藥 有 限 公 司 * （於開曼群島註冊成立的有限公司） （股份代號：2592） 自願公告 業務最新進展 本公告乃由撥康視雲製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）作出的自願公 告，以知會本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事會（「董事會」）欣然宣佈，本公司於美利堅合眾 ...

Core Viewpoint - Cytokinetics reported a narrower net loss in Q3 2025 compared to previous estimates, but revenues fell short of expectations, leading to a mixed outlook for the company as it prepares for upcoming regulatory decisions regarding its lead drug candidate, aficamten [2][3][4]. Financial Performance - The net loss for Q3 2025 was $1.54 per share, which was better than the Zacks Consensus Estimate of a loss of $1.59, but worse than the loss of $1.36 per share reported in the same quarter last year [2]. - Revenues for the quarter totaled $1.9 million, missing the Zacks Consensus Estimate of $6 million, but showing an increase from $0.4 million in the year-ago quarter [3]. - R&D expenses rose by 17.3% year-over-year to $99.2 million, driven by clinical trial advancements and higher personnel costs [4]. - General and administrative expenses increased by 22.6% to $69.4 million, attributed to investments in the commercial readiness of aficamten and personnel-related expenses [4]. - As of September 30, 2025, the company had approximately $1.25 billion in cash and investments, up from $1.04 billion at June 30, 2025 [4]. Drug Development Updates - Aficamten, a cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy (HCM), has had its FDA target action date extended to December 26, 2025 [5]. - Cytokinetics participated in a late-cycle meeting with the FDA regarding aficamten's NDA, discussing its proposed Risk Evaluation and Mitigation Strategy (REMS) [6]. - The company is also addressing questions from the EMA regarding aficamten's marketing authorization application, with a potential decision expected in the first half of 2026 [7]. - Aficamten is being evaluated in multiple clinical trials, including MAPLE-HCM, which reported positive top-line results, and ACACIA-HCM, with results expected in Q2 2026 [8][9]. Pipeline Candidates - Other pipeline candidates include omecamtiv mecarbil, currently in a phase III trial for heart failure, and ulacamten, which is in a phase II trial for heart failure with preserved ejection fraction [10][11]. Market Sentiment and Outlook - Since the earnings release, there has been a downward trend in fresh estimates, with the consensus estimate shifting by 8.51% [12]. - Cytokinetics has a subpar Growth Score of D and a Momentum Score of B, but an overall VGM Score of F, indicating challenges in value [13]. - The stock has a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [14].

Axsome Therapeutics FY Conference Summary Company Overview - **Company**: Axsome Therapeutics (NasdaqGM:AXSM) - **Event**: FY Conference on December 03, 2025 Key Points Industry and Product Updates - **Auvelity and Alzheimer's Disease (AD) Agitation**: - Axsome is awaiting an acceptance decision for the supplemental new drug application (SNDA) for Auvelity in AD agitation, which was submitted in early November [3][5][10] - The expectation is for a standard review due to FDA resource constraints, despite having three positive trials and breakthrough therapy designation [10][11] - The company believes the trial package is robust, consisting of one randomized parallel group study and two randomized withdrawal studies [10][12][22] Commercialization Strategy - **Sales Force Expansion**: - Currently, Axsome has approximately 300 sales representatives detailing for Major Depressive Disorder (MDD) and plans to expand the team upon approval for AD agitation [24][26] - The peak sales opportunity for AD agitation is estimated between $1.5 billion and $3 billion, while MDD is estimated at $1 billion to $3 billion, totaling $2.5 billion to $6 billion [30][32] - A discrete field force team will be established for long-term care facilities, recognizing the comorbidity between MDD and AD agitation [32][34] Market Access and Coverage - **Access to Auvelity**: - Currently, there is 100% access in the government channel and 75% in the commercial channel, leading to an overall 85% total covered lives [47][47] - The majority of prescriptions are expected to come from the government channel, with high-quality access anticipated for the AD agitation indication [47][123] Direct-to-Consumer (DTC) Campaign - **DTC Campaign for Auvelity**: - A national TV DTC campaign launched in September has shown positive results, with new prescriptions (NBRXs) increasing from 2,000 to over 2,800 per week [75][78] - The campaign is expected to continue through 2026, with adjustments made based on market conditions [79][100] Product Performance and Market Position - **Auvelity in MDD**: - Over 50% of prescriptions are now for monotherapy, with 15% first-line and 35% second-line usage [103][108] - The gross-to-net (GTN) improved from mid-50s% in Q1 and Q2 to high 40s% in Q3, with expectations for a slight uptick in Q4 [122][123] Pipeline Developments - **Solriamfetol**: - Axsome is excited about the potential of Solriamfetol in various CNS settings, with studies underway for ADHD, MDD with excessive daytime sleepiness, and binge eating disorder [159][161][186] - The company anticipates starting a pediatric ADHD study this quarter and expects top-line results for binge eating disorder next year [174][190] New Product Development - **GABA-A Alpha 2/3 Modulator**: - Axsome is exploring the value proposition of a new GABA-A modulator for epilepsy and psychiatric indications, with preclinical work already underway [200][206] - The company is taking an opportunistic approach to expand its early-stage pipeline [211][220] Conclusion - Axsome Therapeutics is strategically positioned with a robust pipeline and commercialization plans, focusing on expanding its market presence in both existing and new indications while maintaining a strong emphasis on data-driven decision-making and market access strategies.

Financial Data and Key Metrics Changes - The company announced a $7 billion commitment to expand R&D capabilities and domestic manufacturing [6] - The cash balance remains substantial, with ongoing dividends and buybacks, but the company is open to M&A opportunities if the right conditions arise [11][12] Business Line Data and Key Metrics Changes - Eylea HD received recent approvals for RVO and Q4 dosing, with expectations for commercial impact starting in 2026 [17] - Dupixent continues to grow robustly, treating over 1.3 million patients globally, with significant market expansion opportunities in atopic dermatitis and asthma [30][31] Market Data and Key Metrics Changes - The company is actively monitoring the impact of biosimilars on Eylea, noting that any conversions to biosimilars still position patients as candidates for Eylea HD [24] - The COPD launch has shown strong performance, with Dupixent being the best-performing respiratory launch for the company [34] Company Strategy and Development Direction - The company is committed to domestic manufacturing and enhancing internal capabilities while exploring external opportunities for growth [6][12] - The focus remains on investing in the pipeline and fostering innovation to drive long-term shareholder value [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, particularly regarding the Eylea HD enhancements and the ongoing growth of Dupixent [21][30] - The company is closely watching policy changes related to drug pricing and their potential impact on Eylea and other products [26] Other Important Information - The company is preparing for a submission for a prefilled syringe for Eylea HD, expected in the second quarter [18] - Linvoseltamab has shown promising data in the myeloma market, with plans for further studies in earlier lines of therapy [63] Q&A Session Summary Question: Update on policy and macro environment - The company has committed to domestic manufacturing and is in active negotiations regarding drug pricing policies [6][9] Question: Thoughts on M&A and business development - The company is open to M&A opportunities but prioritizes internal investments and collaborations [12][13] Question: Eylea HD commercial impact and competition - Eylea HD enhancements are expected to drive growth starting in 2026, despite current payer issues [21][24] Question: Dupixent growth drivers - Dupixent is benefiting from market expansion in atopic dermatitis and asthma, with significant room for growth [30][31] Question: Linvoseltamab in myeloma - Linvoseltamab has shown best-in-class data among BCMA bispecifics, with ongoing studies to simplify treatment algorithms [62][63]